Compare INCY & HLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | INCY | HLI |
|---|---|---|
| Founded | 1991 | 1972 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.0B | 14.4B |
| IPO Year | 1993 | 2015 |
| Metric | INCY | HLI |
|---|---|---|
| Price | $102.46 | $179.65 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 20 | 9 |
| Target Price | $90.71 | ★ $205.38 |
| AVG Volume (30 Days) | ★ 2.0M | 367.8K |
| Earning Date | 10-28-2025 | 10-30-2025 |
| Dividend Yield | N/A | ★ 1.34% |
| EPS Growth | ★ 3878.02 | 26.59 |
| EPS | 5.90 | ★ 6.19 |
| Revenue | ★ $4,813,105,000.00 | $2,565,361,000.00 |
| Revenue This Year | $19.59 | $15.23 |
| Revenue Next Year | $10.88 | $13.29 |
| P/E Ratio | ★ $17.37 | $29.04 |
| Revenue Growth | 18.09 | ★ 21.00 |
| 52 Week Low | $53.56 | $137.99 |
| 52 Week High | $109.28 | $211.78 |
| Indicator | INCY | HLI |
|---|---|---|
| Relative Strength Index (RSI) | 54.83 | 49.37 |
| Support Level | $100.55 | $171.77 |
| Resistance Level | $107.61 | $178.75 |
| Average True Range (ATR) | 2.94 | 3.98 |
| MACD | -0.98 | 1.22 |
| Stochastic Oscillator | 45.19 | 81.63 |
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Houlihan Lokey Inc is an investment bank with expertise in mergers and acquisitions, capital markets, financial restructuring, valuation, and strategic consulting. The firm serves corporations, institutions, and governments world-wide with offices in the United States, Europe, and the Asia-Pacific region. The company operates in three segments. In the Corporate Finance business segment, it provides M&A and capital markets advisory services. Through the Financial Restructuring business segment, the company advises on some of the complex restructurings around the world. The Financial and Valuation Advisory Services business segment provides valuation and financial opinion, and financial and strategic consulting practices in the United States.